Innoviva board elected; Sapna Srivastava receives 21.9M against votes

Also at the Meeting, our stockholders next approved one year as the frequency of non-binding advisory votes on Innoviva’s executive compensation. The vote for such approval was 51,448,996 shares for one year, 19,063 shares for two years, 2,986,237 shares for three years, 44,784 shares abstaining and 4,319,019 broker non-votes.

Also at the Meeting, our stockholders next ratified the selection by the Audit Committee of the Board of Directors of Innoviva of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. The vote for such ratification was 58,801,428 shares for, 11,607 shares against, 5,064 shares abstaining and no broker non-votes.

At the Meeting, our stockholders next approved on a non-binding advisory basis, Innoviva’s executive compensation. The vote for such approval was 51,955,275 shares for, 2,512,795 shares against, 31,010 shares abstaining, and 4,319,019 shares of broker non-votes.

At the Annual Meeting of Stockholders held on May 22, 2023 (the “Meeting”), the stockholders of Innoviva, Inc. (“Innoviva”) elected six members to our board of directors, each for a one-year term expiring at the annual meeting of stockholders in 2024, as follows: Members Number of Shares Voted For Number of Shares Voted Against or Abstained Broker Non- Votes Deborah L. Birx, M.D. 53,617,426 881,654 4,319,019 Mark DiPaolo, Esq. 54,180,081 318,999 4,319,019 Jules Haimovitz 53,447,741 1,051,339 4,319,019 Odysseas D. Kostas, M.D. 54,168,478 330,602 4,319,019 Sarah Schlesinger, M.D. 52,929,318 1,569,762 4,319,019 Sapna Srivastava, Ph.D. 32,608,554 21,890,526 4,319,019

Also at the Meeting, our stockholders next approved the Innoviva, Inc. 2023 Employee Stock Purchase Plan. The vote for such approval was 54,298,015 shares for, 130,716 shares against, 70,349 shares abstaining and 4,319,019 broker non-votes.